Applied DNA Sciences, Inc., now trading under the ticker symbol BNBX on NASDAQ, has been named a B2i Digital Featured Company as it completes a strategic rebrand that marks a fundamental shift from its traditional nucleic acid manufacturing toward a yield-focused BNB digital asset treasury strategy. The company, which changed its ticker from APDN to BNBX effective October 7, 2025, is positioning itself at the intersection of biotechnology and digital asset management while retaining its core nucleic acid production capabilities.
The rebranding represents a significant corporate transformation for Applied DNA Sciences, moving from its legacy focus on nucleic acid manufacturing to a broader platform that integrates digital asset management. According to David Shapiro, CEO of B2i Digital, “The company's shift toward a BNB-centric digital asset treasury underscores its commitment to innovation in corporate finance and shareholder alignment. This rebrand signals a strategic move toward greater capital efficiency and digital integration.”
To implement its BNB treasury strategy, Applied DNA has secured approximately $27 million in aggregate gross proceeds through two five-year agreements with Cypress LLC and Cypress Management LLC. The new ticker symbol BNBX directly reflects the company's digital asset focus, a move that is expected to attract investors interested in cryptocurrency exposure within a publicly traded entity.
Clay Shorrock, CEO of Applied DNA Sciences, emphasized the importance of the partnership with B2i Digital in communicating the transformation. “Partnering with B2i Digital enables us to share our transformation and long-term vision with a much wider investor audience. As we execute on our BNB treasury strategy, we believe this collaboration will help investors understand how our approach to digital asset management supports both growth and balance-sheet strength,” Shorrock said.
Despite the strategic pivot toward digital assets, Applied DNA continues to commercialize its nucleic acid production platforms through its LineaRx subsidiary. The company maintains its LineaDNA™, LineaRNAP™, and LineaIVT™ platforms, which enable cell-free manufacturing of DNA and RNA for therapeutics and diagnostics. This dual approach aims to generate yield and token accumulation within the Binance ecosystem while leveraging the company's existing operational technology expertise.
As a B2i Digital Featured Company, Applied DNA will gain access to B2i Digital's network of over 1.4 million investors across multiple digital platforms, including LinkedIn, X, and Facebook. The campaign will feature dedicated digital content, investor presentations, and company updates designed to communicate Applied DNA's strategic transformation at scale, providing broad exposure to both retail and institutional investors.
The strategic shift represents a significant development in corporate adoption of digital asset strategies, particularly in how traditional companies are integrating cryptocurrency treasury management into their core business operations. Applied DNA's approach combines its established biotechnology expertise with emerging digital asset management, creating a unique corporate model that could influence how other companies approach cryptocurrency integration and treasury management strategies.
